LA02 + LF10 (ACTICAND)
Gynecology
Candida
Inhibits the growth of pathogenic Candida, causative agent of vulvovaginal Candidiasis
Supports vaginal health
Mitigates vulvovaginal Candidiasis
1, 2) LA02 400 million CFU + LF10 400 million CFU + Carbon dioxide + FOS + Arabinogalactan
Blend
Finished dosage form
1) Vicariotto F. et al. Effectiveness of the association of 2 probiotic strains formulated in a slow release vaginal product, in women affected by vulvovaginal candidiasis: a pilot study. J Clin Gastroenterol. 2012; 46Suppl:S73-80. DOI: 10.1097/MCG.0b013e3182684d71
2) Murina F et al. Can Lactobacillus fermentum LF10 and Lactobacillus acidophilus LA02 in a Slow-release Vaginal Product be Useful for Prevention of Recurrent Vulvovaginal Candidiasis? A Clinical Study. J Clin Gastroenterol 2014;48:S102-S105. DOI: 10.1097/MCG.0000000000000225
a) Deidda F. et al. The In Vitro Effectiveness of Lactobacillus fermentum Against Different Candida Species Compared With Broadly Used Azoles. J Clin Gastroenterol. 2016 Nov/Dec;50 Suppl 2, S171-S174. DOI: 10.1097/MCG.0000000000000686
